These studies have resulted in the identification of a plethora of resistance mechanisms as well as multiple molecular targets (discussed in Section 7), with the targeting of CDK4/6 (discussed below, Section 3) being one of the most successful improvements in the treatment of ER+, HER2/NEU negative breast cancer (40–42). Here, ERBB2 is linked to breast cancer.